VolitionRx (NYSE:VNRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Wednesday,Benzinga reports. D. Boral Capital currently has a $5.00 target price on the stock.

Separately, HC Wainwright reduced their target price on VolitionRx from $2.50 to $1.50 and set a “buy” rating on the stock in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $3.17.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.31 on Wednesday. The firm’s 50-day moving average is $0.47 and its two-hundred day moving average is $0.58. The company has a market capitalization of $38.23 million, a PE ratio of -0.86 and a beta of 1.24. VolitionRx has a 12-month low of $0.29 and a 12-month high of $0.94.

Insider Buying and Selling

In other VolitionRx news, CEO Cameron John Reynolds purchased 110,000 shares of VolitionRx stock in a transaction on Tuesday, October 14th. The shares were bought at an average price of $0.51 per share, with a total value of $56,100.00. Following the purchase, the chief executive officer directly owned 2,534,847 shares in the company, valued at $1,292,771.97. This trade represents a 4.54% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Guy Archibald Innes acquired 96,153 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The shares were acquired at an average price of $0.51 per share, for a total transaction of $49,038.03. Following the acquisition, the director directly owned 1,062,967 shares of the company’s stock, valued at approximately $542,113.17. The trade was a 9.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 289,229 shares of company stock worth $146,557. 10.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On VolitionRx

Several large investors have recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC boosted its stake in VolitionRx by 42.8% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock worth $153,000 after buying an additional 60,209 shares during the last quarter. Blair William & Co. IL purchased a new position in shares of VolitionRx during the 2nd quarter worth about $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of VolitionRx in the second quarter worth approximately $52,000. Armistice Capital LLC boosted its position in shares of VolitionRx by 3.5% in the second quarter. Armistice Capital LLC now owns 8,493,074 shares of the company’s stock worth $6,455,000 after acquiring an additional 286,644 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in VolitionRx in the third quarter valued at approximately $28,000. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.